posted on 2016-10-17, 00:00authored byKari E. Hernandez, Hans Renata, Russell D. Lewis, S. B. Jennifer Kan, Chen Zhang, Jared Forte, David Rozzell, John A. McIntosh, Frances H. Arnold
Extending the scope of biocatalysis
to important non-natural reactions
such as olefin cyclopropanation will open new opportunities for replacing
multistep chemical syntheses of pharmaceutical intermediates with
efficient, clean, and highly selective enzyme-catalyzed processes.
In this work, we engineered the truncated globin of Bacillus subtilis for the synthesis of a cyclopropane
precursor to the antithrombotic agent ticagrelor. The engineered enzyme
catalyzes the cyclopropanation of 3,4-difluorostyrene with ethyl diazoacetate
on a preparative scale to give ethyl-(1R, 2R)-2-(3,4-difluorophenyl)-cyclopropanecarboxylate in 79%
yield, with very high diastereoselectivity (>99% dr) and enantioselectivity
(98% ee), enabling a single-step biocatalytic route to this pharmaceutical
intermediate.